申请人:HOFFMANN LA ROCHE
公开号:WO2002006254A1
公开(公告)日:2002-01-24
The present invention is concerned with 2H-tetrazole-5-yl-amide derivatives of general formula (I) wherein R1 signifies hydrogen, lower alkyl, -(CH¿2?)n-CF3, -(CH2)n-CHF2, -(CH2)n-CN, -(CH2)n-cycloalkyl, -(CH2)n-O-lower alkyl, -(CH2)n-O-cycloalkyl or -(CH2)n-C(O)O-lower alkyl; R?2¿ signifies hydrogen, lower alkyl, lower alkoxy, halogen, -C(O)-lower alkyl, -C(O)OH, -C(O)O-lower alkyl, -NR3R4 or -C(O)-NR3R4 and wherein R?3 and R4¿ may be independently from each other hydrogen or lower alkyl; X signifies -O-, -S-, -CH¿2?, -OCH2- or two hydrogen atoms not forming a bridge; and n signifies 0, 1, 2, 3 or 4; as well as with their pharmaceutically acceptable salts. It has been found that the compounds of general formula (I) are group 1 metabotropic glutamate receptor agonists (mGluR) and are therefore useful in the treatment of corresponding CNS-disorders.